Video

How do we get the next 10 years right? w/ Joanna Shields, CogX

For the opening keynote of CogX 2020, our CEO Joanna Shields shared inspiration for the next decade, and answered the question “how do we get the next 10 years right”?

We had entered 2020 with such high hopes and dreams for the innovations that awaited us in the coming decade. Yet we were barely out of the gates when our world of infinite possibilities was brought to its knees by a deadly virus. The challenges that followed have been unprecedented in our lifetimes. 

As the disease raged through our communities and lockdowns were enforced, we all watched the daily news recount the number of souls who had lost their lives to COVID-19.  The profound economic shock continues to reverberate, and expose deep inequities in our society and in how we care for our citizens.

Our journey into this strange new normal also made us painfully aware of our own vulnerabilities and the fragility of human life. Above all, we have been reminded that our most valuable currency is not measured in wealth or possessions, but rather through our health.  

So, why can’t we build a world where no disease goes untreated? Why, with all of the advances in technology, are so many people still suffering from disease? The economic and development models urgently need to change. Patients deserve better. We must leverage breakthrough technologies for the benefit of all.

Above all, getting the next 10 years right demands leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all.

Watch the full speech here:


More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022